Merck reports new data from comparative trials with Sitagliptin (CompoSIT)
Merck announced data from the Comparative Trials with Sitagliptin (CompoSIT) clinical trials with JANUVIA® (sitagliptin). In the CompoSIT-I study, initiation of insulin therapy while continuing treatment with JANUVIA resulted in greater blood glucose reductions and more patients reaching A1C goal. June 23, 2018